¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧÕæÌâ
¼¶±ð: Öм¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-06-14   

µÚËľüÒ½´óѧÕæÌâ

ѧ¿Æרҵ£º´«È¾²¡Ñ§ RoGwK*j0+  
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ y !$alE  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö)1. ICAM-12. interleukin 12(IL-12)3. tumor infiltrating lymphocyte4. TCR/CD3 complex5. hematopoietin receptor family 6. individual idiotype(IdI)7. integrin8. colony-stimulatory factor (CSF) 7JJ/D4uT  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? yS(}:'`r  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óá£4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ e=vsuqGT  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö)1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? 2 dp>Z",  
µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ azQD >  
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ L|-98]8>  
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ $$APgj"|<  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©1. CD42. T cell receptor(TCR)3. immunoglobulin superfamily (IgSF)4. selectin 5. anti-idiotypic antibody (¦ÁId)6. major histocompatibility complex(MHC)7. immunotolerance 8. biological reponse modifier(BRM)9. immune reponse gene (Ir gene)10. reshaped antibody (or reconstituted antibody) 8K(Z0  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬?3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? Q\ /uKQ  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) "tFx hKf  
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ?2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? 8to8!(  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨?2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? 7 >iU1zy  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ;Gx)Noo/>  
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ gz2\H}  
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ GdV1^`M6  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©1. CD8 2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â )3. immunoglobulin fold(Ig fold)4. cadherin (Ca-dependent cell adhesion moleculers)5. idiotype-anti-idiotypic antibody immune network theory6. HLA class II antigen 7. complementarity-determining region (CDR)8. perforin(or pore-forming protein ,PFP)9. high affinity IL-2 receptor 10. artificial active immunization o<IAeH {+  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óá£2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ \^I>Q _LU  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£)1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨?3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ^7zu<lX  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ n  -(  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ WJ<^E"^  
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ Bqma\1cgb  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©1. immunoglobulin gene rearrangement 2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors)3. flow cytometry(FCM)4. carrier effect5. positive selection of T lymphocytes in thymus6. mouse TH1(Th1) and TH2(Th2) subsets 7.perforin(pore-forming protein,PFP)8. ADCC(antibody-dependent cell-mediated cytotoxicity)9. SH-2(src-homology region 2)10. Ab2¦Â (internal image) v8AS=sY4r  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹?2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ?3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óá£4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Ҫϲ»¶×÷²½Öè¡£5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ2'=T[<nNB  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) AJ#Nenmj  
ÃâÒßѧרҵ£º1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? iq( )8nxi  
´«È¾²¡Ñ§×¨Òµ£º1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ WA dCF-S  
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? dy_:- 2S  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ eX@L3BKp  
ÃâÒßѧÊÔÌâ h=;{oY<V)?  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©1. Fas(CD95)/FasL2. common chain of cytokine receptor 3 . TCR/CD3 complex4. negaive selection of thymocytes 5. artificial active immune6. anti-idiotypic 7. IgSF 8. Integrin 9. chemokine 10. B7/CD28 Eke5Nb  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 6@DF  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ ]_N|L|]M  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©1. B7/CD282. Th1 subset3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©4. antibody affinity maturation5. AP-1.6. single chain variable fragment£¨ScFv£©7. NK cell receptor8. Zinkernagel-Doherty phenomenon9. Ig fold10. CD40/CD40L vWAL^?HUP  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ $DG?M6   
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ )1X#*mCxk  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ sQkhwMg  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 5\z `-)  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© #%DE;  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©1.Co-stimulators (or co-stimulating molecules)2.NK-kB3.Immunoglobulin superfamily4.antigen-presenting cell (APC)5.death domain6.CCR and CXCR7.Lectin (or mitogen)8.Clusters of differentiation, CD)9.B7 family10.Cytotoxic T lymphocyte, CTL)11.IL-15 and IL-15 receptor (IL-15R)12.MHC restriction13.Affinity-chromatography14.Cyctosprin A, CsA15.Antibody-dependent cell-mediated cytotoxicity, ADCC) -GxaV #{  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 yPq'( PV  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© /Rl6g9}  
ÃâÒßѧרҵ£º1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ $|8!BOx8t  
Ïû»¯ÄÚ¿Æ£º2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Bz,?{o6s)Q  
ѪҺ²¡Ñ§×¨Òµ£º3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ =>-Rnc @  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 'inFKy'H  
(רҵ»ù´¡: ÃâÒßѧ) F w?[lS  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)1. ADCC(antibody dependent cell-mediated cytotoxicity)2. »·æß¾úËØ(cyclosporin)3. KIR(killer cell inhibitory receptor)4. HLDA(human leucocyte differentiation antigen)5. Interleukin 18(IL-18)6. ÕûºÏËØ(integrin)7. Fas/FasL8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)10. Th1/Th211. »ùÒòÒßÃç(DNAÒßÃç)12. chemokines and chemokine receptor13. ÃâÒßÄÍÊÜ14. ¹²´Ì¼¤·Ö×Ó15. ËÀÍö½á¹¹Óò(death domain) FJMrs[  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣣ¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨(3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ì壨4£©1987Äê: Ig»ùÒòµÄ½á¹¹3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ WlU0:(d  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) Zu7)gf  
ÎÊ´ðÌâ(ÿÌâ25·Ö)1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£ >7 ="8  
µÚËľüÒ½´óѧһ¾Å¾Å°ËÄ격ʿѧλÑо¿ÉúÈëѧÊÔÌâ @{2 5xTt  
·Ö×ÓÉúѧ(2)¡ª¡ª×¨Òµ»ù´¡ uA< n  
Ò»¡¢½âÊÍÏÂÁÐÃû´Ê£¨Ã¿Ìâ5·Ö£¬¹²40·Ö£©1. µ°°×¼¤Ã¸(protein kinase)2. ÔöÇ¿×Ó(enhancer)3. SH2½á¹¹Óò(SH2 domain)4. ¾ÛºÏøÁ´·´Ó¦(PCR)5. »ùÒòÖÎÁÆ(gene therapy)6. ±äÐÔµ°°×ÖÊ(denatrued protein)7. ÐźÅëÄ(signal peptide)8. cDNAÎÄ¿â kDsFR#w&`  
¶þ¡¢ÎÊ´ðÌâ(Ñ¡´ðËĵÀÌâ,¹²¼Æ60·Ö)1. ʲôÊǵ°°×ÖʵÄÒ»¼¶¡¢¶þ¼¶¡¢Èý¼¶¡¢Ëļ¶½á¹¹£¿ËüÃÇÒÀ¿¿Ê²Ã´ÑùµÄÁ´ºÍÁ¦½¨Á¢ÆðÕâЩ½á¹¹£¿ËüÃÇÖ®¼äµÄ¹ØϵÊÇʲô£¿(15·Ö)2. ¼òÊöÖØ×éDNA¼¼ÊõµÄ¶¨Òå¡¢Ô­ÀíºÍÖ÷Òª¹ý³Ì£¬½áºÏÄãµÄרҵ¾Ù³öÒ»¸öÓ¦Óøü¼ÊõµÄʵÀý²¢ËµÃ÷ÆäÒâÒå¡£(15·Ö)3. ¼òÊö°©»ùÒòÓëÒÖ°©»ùÒòµÄ¶¨Òå,¸÷¾ÙÒ»Àý˵Ã÷ÆäÔÚÖ×Áö·¢ÉúÖеÄ×÷Óá£(15·Ö)4. ÒÔÈéÌÇϲ»¶×Ý×Ó(»ò³ÆΪÈéÌÇϲ»¶×ÝÔª)ºÍÉ«°±Ëáϲ»¶×Ý×ÓΪÀý¼òÊöÔ­ºËϸ°û»ùÒò±í´ïµ÷¿ØÔ­Àí¡£(15·Ö)5.¼òÊöÕæºËϸ°û»ùÒò±í´ïµ÷¿ØµÄ»ù±¾»·½Ú¡¢Ö÷ÒªµÄµ÷¿Ø·Ö×Ӻ͵÷¿Ø·½Ê½¡£(15
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
Çå¿ÕÎÒµÄÆÀ·Ö¶¯Ì¬±¾Ìû×î½üÆÀ·Ö¼Ç¼: ¹²1ÌõÆÀ·Ö¼Ç¼
nanafly ²Æ¸» +5 2007-06-14 -
Òþ²ØÆÀ·Ö¼Ç¼
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»